Skip to main content
Nov 2, 2020

You Are Invited to Participate in a Hyperkalemia Patient Drug Review Survey

As part of our ongoing advocacy efforts, The Kidney Foundation submits patient feedback to patient drug reviews such as the Common Drug Review (CDR) and Institut national d’excellence en santé et en services sociaux (INESSS).  

We are currently seeking information from people living with Chronic Kidney Disease and their caregivers regarding their experience with treatments for hyperkalemia (high potassium), including Veltassa (patiromer). The Kidney Foundation of Canada is preparing a patient input submission to the CDR, INESSS and provincial evaluations for this medication. Responses to this survey will inform this submission.

The CDR evaluates a drug then makes a recommendation and advises on what drugs should be covered by federal, provincial and territorial drug programs (except Quebec).  Patient groups, such The Kidney Foundation gather input from patients and caregivers to provide input into the CDR.  Patients can inform us of what’s important to them and what they would value in a new treatment.  

INESSS’s mission is to promote clinical excellence and the efficient use of resources in the health and social services sector.

Find out more or take the survey

NOTE: The Kidney Foundation does not recommend or endorse any medication.

Please note you are viewing content from another region. The information provided here may not be available in your area.